Track topics on Twitter Track topics that are important to you
Thomas w. Samuelson
WASHINGTON — Patients who received an iStent inject with phacoemulsification experienced clinically significant reductions in unmedicated diurnal IOP compared with patients who underwent phacoemulsification alone, according to 24-month study results.
The prospective, randomized, controlled trial included 387 patients with mild to moderate open-angle glaucoma who received the iStent inject (Glaukos) and underwent phacoemulsification and 118 patients who underwent phacoemulsification alone.
According to a company press release, “The iStent inject is designed to
Original Article: iStent inject with phaco yields clinically significant IOP reductionNEXT ARTICLE